
Journal of Medicinal Chemistry p. 1273 - 1279 (1992)
Update date:2022-08-04
Topics:
Lawrence
Venepalli
Appell
Goswami
Logan
Tomczuk
Yanni
The synthesis of unsymmetrical naphth[2,3-d]imidazolium and bridged naphth[2,3-d]imidazolium derivatives and their substance P (SP) antagonist activity are described. All compounds were evaluated for their ability to displace SP from neurokinin-1 (NK-1) receptor sites using standard receptor binding methodology (rat forebrain membrane). 1,3-Diethyl-2-[3-(1,3-dihydro- 1,3,3-trimethyl-2H-indol-2-ylidene)-1-propenyl]-1H-naphth[2,3-d]imidazolium chloride (7a), a representative compound in this series, was further evaluated for SP antagonist activity in a guinea pig ileum contractility assay. In vivo SP antagonist activity of 7a was demonstrated using SP-induced salivation and paw edema models performed in rats.
View Moretaizhou creating bio-pharm co.,ltd.
Contact:+86- 576- 88827176
Address:715 room ,unit A.junyue Building,Jiaojiang,Taizhou,Zhejiang,China
ALPHA PHARMACEUTICAL CO,LTD JIANGSU
Contact:+86-527-84829968,+86-527-84829998
Address:suqian city
Shanghai Yingrui Biopharma Co., Ltd
Contact:021-3358 8661*8003
Address:shanghai
XI'AN CHUKANG BIOTECHNOLOGY CO.,LTD
Contact:29-63685658 63685359
Address:Room 3-1202,Building 1,Oriental oasis,East of Xianning Road,Xi'an,Shaanxi 710043 P.R.China
Huludao Tianqi Shengye Chemical Co.,Ltd.
Contact:0086 429 2075777
Address:Area B,Shipbuilding Industry Park,Beigang District,Huludao City,Liaoning prov.,China
Doi:10.3906/kim-1110-43
(2012)Doi:10.1002/ejoc.201200158
(2012)Doi:10.1016/j.jorganchem.2012.05.023
(2012)Doi:10.1039/C5RA27624A
(2016)Doi:10.1021/jacs.0c02721
(2020)Doi:10.3109/14756366.2011.597748
(2012)